Feature | Atrial Fibrillation | July 20, 2015

Study Reveals Racial Gender Disparities in Care for New Atrial Fibrillation Patients

White patients and male patients found to receive most care compared to women and minorities

July 20, 2015 - A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with atrial fibrillation (AF). The study, published in the July edition of HeartRhythm, the official journal of the Heart Rhythm Society (HRS), includes data from more than 500,000 Medicare beneficiaries. Results notably indicate that female patients compared to male patients are less likely to receive oral anticoagulation, a medication used to lower the likelihood of experiencing a stroke. Women are also less likely than men to receive an ablation, as were Hispanics versus whites.

The study found statistically significant differences in the use of AF-related services by both race and gender, with white patients and male patients receiving the most care. Specifically, women were less likely than men to receive anticoagulation (35 versus 38.8 percent), and both blacks and Hispanics were less likely than whites (30.5 vs. 31.4 vs. 37.3 percent). Women were also less likely than men to receive an ablation (0.6 vs. 1.3 percent), as were Hispanics versus whites (0.6 vs. 0.9 percent). Hispanics and women were less likely to have an outpatient clinic visit with an electrophysiologist (EP) compared to their counterparts. Other differences were also seen in rate- and rhythm-controlling medications.

More than 500,000 (517,941) Medicare patients newly diagnosed with AF were compared using collective data from the Centers for Medicare and Medicaid (CMS) during 2010-2011. The usage of medical services within 90 days of initial AF diagnosis was cataloged to determine any racial or gender differences. The services analyzed included: visit to a cardiologist; visit to an EP; and use of anticoagulation, rate-controlling medications, rhythm-controlling medications or radiofrequency ablation.  

"While we have seen racial and gender differences in the care of other cardiac conditions, our study is the first to broadly look at and show disparities in the receipt of care specifically for AF. Particularly, it was of concern to see that women were less likely to receive oral anticoagulation since they are at greater risk of stroke compared to men," said Prashant Bhave, M.D., FHRS, clinical assistant professor in the Department of Internal Medicine for University of Iowa Health Care. "It is essential that each patient is treated with a consistent standard of care, regardless of race or gender. Increasing awareness about AF and effective therapy options is one step we need to take to help narrow this health equity gap."

The study authors note that identifying patterns of disparity and barriers to care at the regional and local level may help to guide community-based interventions. Strategies to educate patients, change patterns of referral, and improve access to specialty care for women and minorities with AF may help to improve the quality of life and outcomes in those patients.

HRS works throughout the year to increase public knowledge of AF, including its symptoms, warning signs, and available treatment options.

For more information: www.hrsonline.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now